    DISCLAIMER
    The information in this presentation was prepared by EBOS Group Limited (“EBOS” or the “Group”) with due care and attention. However, the information is supplied in summary form and is therefore
    not necessarily complete, and, to the extent permitted by law, no representation is made as to the accuracy, completeness or reliability of the information. In addition, neither EBOS nor any of its
    subsidiaries, directors, employees, shareholders nor any other person shall have liability whatsoever to any person for any loss (including, without limitation, arising from any fault or negligence)
    arising from this presentation or any information supplied in connection with it.

    This presentation may contain forward-looking statements and projections. These reflect EBOS’ current expectations, based on what it thinks are reasonable assumptions. To the extent permitted by
    law, EBOS gives no warranty or representation as to its future financial performance or any future matter. Except as required by law or NZX or ASX listing rules, EBOS is not obliged to update this
    presentation after its release, even if things change materially. This presentation does not constitute financial advice. Further, this presentation is not and should not be construed as an offer to sell or
    a solicitation of an offer to buy EBOS securities and may not be relied upon in connection with any purchase of EBOS securities.

    This presentation contains a number of non-GAAP financial measures, including Gross Operating Revenue, EBITDA, EBIT, NPAT, Underlying Operating Expenditure, Underlying EBITDA, Underlying
    EBIT, Underlying NPAT, Underlying Earnings per Share, Free Cash Flow, Underlying Cash from Operations, Underlying Free Cash Flow, Cash Conversion Days, Net Working Capital, Net Debt, Leverage,
    Net Debt : EBITDA and Return on Capital Employed (ROCE). Because they are not defined by GAAP or IFRS, EBOS’ calculation of these measures may differ from similarly titled measures presented by
    other companies and they should not be considered in isolation from, or construed as an alternative to, other financial measures determined in accordance with GAAP. Although EBOS believes they
    provide useful information in measuring the financial performance and condition of EBOS' business, readers are cautioned not to place undue reliance on these non-GAAP financial measures.

    The information contained in this presentation should be considered in conjunction with the audited consolidated financial statements for the full year ended 30 June 2025.

    EBOS and its businesses are subject to known and unknown risks, some of which are beyond the control of EBOS and/or may not be fully mitigated. A summary of key financial and non-financial risks
    identified by EBOS can be found under ‘Risk Management’ at https://www.ebosgroup.com/who-we-are/corporate-governance. This should not be considered an exhaustive list.

    All currency amounts are in Australian dollars unless stated otherwise.

    Underlying earnings for the 30 June 2025 and 30 June 2024 periods exclude M&A transaction costs, non-recurring restructuring and site transition costs and the amortisation (non-cash)
    expense attributable to purchase price accounting (PPA) of finite life intangible assets.

    To provide a like-for-like comparison to the prior corresponding period, where applicable, this presentation includes comparisons against Underlying earnings exclusive of the estimated
    earnings from the Chemist Warehouse Australia (CWA) contract for the 30 June 2024 period.




2
    EXECUTIVE SUMMARY
                                                    •    Ongoing organic growth driven by ~$385m revenue from new pharmacy wholesale customers and
                                                         double-digit growth in Southeast Asia within Medical Technology, with total underlying Group EBITDA
    Solid FY25                                           growth of 7.5% (excl. CWA)1
    performance                                     •    Disciplined cost management, delivering 20bps cost-out2
                                                    •    Strategic execution continued, with all FY25 growth objectives met and EBITDA delivered within guidance


                                                     •   Completing the distribution centre renewal program in FY26, which will have delivered 8 new sites over
    Maintain focus on                                    4 years (FY23-FY26). FY26 will see the conclusion of this program with the final $130 – 140m capex
    capital investment                                   investment
    & allocation                                     •   Bolt-on acquisition program continues in FY26, with purchase of Next Generation Pet Foods3,
                                                         expanding into high growth premium air-dried treats and enhancing manufacturing capability




                                                     •   A leading pharmaceutical wholesaler in Australia and New Zealand
    Portfolio                                        •   The leading health-services focussed community pharmacy network in Australia
    positioned well for                              •   Australia and New Zealand’s leading hospital medicines wholesaler and one of ANZ and Southeast
    long-term growth                                     Asia’s leading medical technology distributors
                                                     •   ANZ’s largest dry dog food brand4 in pet specialty and ANZ’s leading vet wholesaler




                                                                                                       Ongoing advantage: trusted to connect to care

    1.   Growth is FY25 Underlying compared to FY24 Underlying when normalised to exclude the CWA contract
    2.   Cost out defined as: Operating expenditure as a % of revenue (excluding CWA contract)
3   3.   Next Generation Pet Foods was completed on 1 July 2025
    4.   Measured by volume
    FY25 PERFORMANCE
    FY25 result in line with guidance, reflecting strong Underlying growth1, supported by strategy execution




                     Revenue                                        Underlying EBITDA                                          Underlying EPS

              $12,267m                                                     $585m                                               131.3 cps
             +12.0% excl. CWA1                                        +7.5% excl. CWA1

            Statutory Revenue                                         Statutory EBITDA                                           Statutory EPS
                 $12,267m                                                  $556m                                                   109.7 cps
                  (-7.0%)                                                  (-8.3%)                                                  (-22.4%)




               Leverage ratio2                                                  ROCE3
                                                                                                                              Full year dividend
                    1.92x                                                   13.0%                                          NZ 118.5 cps
         1.89x as at 30 June 2024                                     -20bps excl. CWA1
                                                                                                                             Consistent with FY24




    1.   Growth is FY25 Underlying compared to FY24 Underlying when normalised to exclude the CWA contract.
4   2.   Calculated in accordance with banking covenants and excludes IFRS 16 lease impacts.
    3.   ROCE as at 30 June 2025 and ROCE growth (based on comparison to 30 June 2024) are normalised to exclude the CWA contract.
         DIVISION HIGHLIGHTS
         Solid organic growth across both Healthcare and Animal Care segments, supplemented with strategic acquisitions

                               Community Pharmacy                                             Institutional Healthcare                    Contract Logistics                         Animal Care




                        •    ~$540m annualised revenue from                              •    Continued strong growth in          •   New customer growth in Australia   •   Branded product revenue growth
                             new pharmacy wholesale                                           hospital medicines, particularly        and New Zealand, enabled by new        of 4.1%, supported by new product
                             customers                                                        oncology products                       warehouse capacity                     development launches
                        •    TWC store network grew to over                              •    Strong growth in Medical            •   Australian business GOR grew by    •   SVS acquisition established a
                             620 stores (+34 stores full year)                                Technology in both ANZ and              15%                                    leading position in NZ vet
                                                                                              Southeast Asia, with revenue                                                   wholesale sector
                        •    First Pharmaceutical Wholesaler
                                                                                              growth of 18.6%
                             Agreement signed                                                                                                                            •   Next Generation Pet Foods
                                                                                         •    Two strategic acquisitions in                                                  acquisition provides entry to new
                                                                                              Medical Technology, expanding our                                              high growth, high value products
                                                                                              Southeast Asia presence in the                                                 and expanded manufacturing
                                                                                              Philippines and Malaysia                                                       capacity2
                                                                                                                                                                                         13%
                                                                                                                                              9%
     FY25 GOR                                                  36%
    contribution
                                                                                                              42%

     FY25 GOR
      growth
                                                +7.0%1                                                            +11.4%                           +3.3%                                  +10.1%


         1.   Growth is FY25 Underlying compared to FY24 Underlying when normalised to exclude the CWA contract
5        2.   Next Generation Pet Foods acquisition completed 1 July 2025
    NEAR-TERM GROWTH OBJECTIVES ACHIEVED
    Continued delivery against strategy with all initiatives achieved

                                                                                  Progress to date                                                                                  Status

    Base business growth
    Healthcare and Animal Care
    segments to record positive organic
    growth, excluding the CWA contract
                                                                                  Underlying EBITDA growth for Healthcare and Animal Care was +6.9% (ex. CWA1) and
                                                                                  +10.4% respectively                                                                              ✓✓
    Community Pharmacy revenue wins
    $300m+ new pharmacy wholesale
    revenue
                                                                                  Generated ~$385m revenue from new pharmacy wholesale customers in FY25 (or
                                                                                  ~$540m+ annualised)                                                                              ✓✓
    Cost reduction
    initiatives
    $25-50m of costs savings by the end of
    FY26
                                                                                  Cost savings of $30m achieved in FY25, through COGS, labour, freight, packaging and
                                                                                  administrative costs, delivering 20bps cost-out2                                                    ✓
    M&A
    A strategic focus, targeting
    opportunities that strengthen the core
    and diversify and grow earnings
                                                                                  Five3,4 investments executed for approximately $210m total capital deployed, across
                                                                                  Medical Technology and Animal Care                                                               ✓✓
                                                                                                                                            Legend: Achieved ✓✓     In-flight and on-track ✓

    1.   Growth is FY25 Underlying compared to FY24 Underlying when normalised to exclude the CWA contract
    2.   Cost out defined as: Operating expenditure as a % of revenue (excluding CWA contract)
6
    3.   Includes Next Generation Pet Foods that was completed on 1 July 2025
    4.   Two additional small acquisitions were completed in FY25 and not noted above
    ENVIRONMENTAL, SOCIAL, GOVERNANCE PROGRAM
    We recognise our responsibility as a provider of essential network infrastructure, products, and services to improving both human and animal
    health outcomes.


         Our sustainability pillars                       ESG highlights
                                                          • Progressed toward generating renewable
                                                            electricity to match forecasted FY27 Australian
                                                            operations usage
                                                          • 95%1 of grocery brand packaging to be recyclable
                                                            by early 2026
                                                          • $400,000+ donated to Greenfleet in FY25, $2.4
                                                            million+ since 2007
                                                          • Acquired South Gippsland, Victoria property for
                                                            reforestation, with ~94 hectares of planting
                                                            potential
                                                          • Launched “Life Savers” to reduce high-risk work
                                                            hazards and enhance critical risk focus
                                                          • Continued investment in ‘Catalyst’ leadership
                                                            development program, achieving 50% female
                                                            participation




7   1.   Packaging percentages relate to number of SKUs
    HEALTHCARE SEGMENT
    A strong performance (ex. CWA1), supported by customer wins and strategic acquisitions
                                                                                                        Var%
         $m                      FY25                            FY24              Var%               ex CWA1   • Australian Healthcare business grew revenue by 12.9% and Underlying
          Revenue               11,593                          12,610             (8.1%)              11.8%      EBITDA by 5.9% (ex. CWA1) led by Community Pharmacy, TWC, Institutional
          GOR                    1,422                           1,438             (1.1%)               8.6%      Healthcare and Contract Logistics
          Underlying EBITDA       500                             548              (8.7%)               6.9%
                                                                                                                • New Zealand and Southeast Asia grew revenue by 8.1% and Underlying
          GOR%                  12.3%                           11.4%              90bps               -30bps
                                                                                                                  EBITDA by 10.8% driven primarily by double-digit growth in Southeast Asia
          Underlying EBITDA%     4.3%                            4.3%                 -                -20bps
                                                                                                                  and growth in New Zealand, excluding COVID-19 related products
         Australia
          Revenue                8,958                          10,173             (11.9%)             12.9%    • GOR margin expansion reflects a shift in product and customer mix in
          Underlying EBITDA       397                            455               (12.7%)              5.9%      Community Pharmacy, and the growth of both Medical Technology and TWC
          Underlying EBITDA%     4.4%                            4.5%               -10bps             -30bps
         New Zealand & Southeast Asia
          Revenue                2,635                           2,437               8.1%                8.1%
          Underlying EBITDA       103                              93               10.8%               10.8%
          Underlying EBITDA%     3.9%                            3.8%               10bps               10bps

         Underlying EBITDA ($m and %)
                         3.7%               3.8%               4.4%               4.3%               4.3%




                                                               517                548                 500
                         320                390


                         FY21               FY22               FY23               FY24               FY25
                                   Underlying EBITDA                           Underlying EBITDA%




9   1.    Growth is FY25 Underlying compared to FY24 Underlying when normalised to exclude the CWA contract
COMMUNITY PHARMACY
A leading pharmaceutical wholesaler in Australia and New Zealand



                                                                                                          • Revenue and GOR increased by 15.8% and 7.0%
                                                                                         Var%
     $m                                   FY25            FY24           Var%           ex CWA1             (ex. CWA1) respectively, driven by:
      Revenue                             6,456           7,810         (17.3%)          15.8%                -   Pharmacy wholesale growth from both existing
      GOR                                  588             678          (13.3%)           7.0%                    and new customers (including ~$385m revenue
      GOR%                                 9.1%           8.7%           40bps           -80bps                   and +320 stores from new wins)

                                                                                                              -   Strong demand for high value medicines, e.g.
                                                                                                                  GLP-1, autoimmune, and cardiology medicines
 Revenue and GOR ($m)
                                                                 678                                      •   GOR margin improved to 9.1%, reflecting shift in
                                               646
                              569                                                 588                         product/customer mix, new business wins and
            499
                                                                                                              enhanced services revenue

                                                                                                          •   The First Pharmacy Wholesaler Agreement was
                                             7,312             7,810
                            6,442                                               6,456                         signed in December 2024 and provided a modest
          5,390
                                                                                                              funding increase in H2 FY25, with a further
                                                                                                              increase from FY27
          FY21               FY22             FY23              FY24             FY25
                              Revenue                                  GOR




10          1.    Growth is FY25 Underlying compared to FY24 Underlying when normalised to exclude the CWA contract
TerryWhite Chemmart1
The leading health-services focussed community pharmacy network in Australia, administering ~1 million vaccinations and filling ~1.2 million
prescription transactions online in FY25



• Added 34 net new stores to TWC’s national network, continuing its impressive growth
  in pharmacy numbers and growing to over 620 stores

• Strong trading performance with network sales of $2.6bn, up 10.2% and like-for-like
  sales up 8.5%. Dispensary sales up 13.0% and like-for-like sales up 11.2%

• TWC network remained provider of choice for health services administering ~1 million
  vaccinations, attributable to the expansion of the CareClinic service offering

• TWC consumer brand sales grew 28%, supported by the launch of new products,
  providing an excellent value option to both customers and network partners

• TWC won the 2025 Asia Pacific Award – Best Loyalty Marketing Campaign for the TWC
  REWARDSPlus program2 with membership that has grown to more than 2.5 million

• Enhanced customer convenience through our e-commerce offering with over 1.2 million
  prescription transactions placed online and through the MyTWC app




       1.   TerryWhite Chemmart results are reported within Community Pharmacy
11
       2.   Awarded from the Australian Loyalty Association
INSTITUTIONAL HEALTHCARE
Australia and New Zealand’s leading hospital medicines wholesaler and one of ANZ and Southeast Asia’s leading medical technology distributors



 Revenue and GOR ($m)                                               • Revenue and GOR increased by 8.4% and 11.4%
                                                       680            respectively
                                 570       611
                                                                    • Medicines, consumables and other revenue grew
                     378
           256
                                                                      by 6.8%, driven by:
                                                                        - Continued growth from high value hospital
                                           4,005       4,342
                                 3,590                                   medicines, including demand for oncology
           2,686    3,070
                                                                         medicines
           FY21     FY22         FY23      FY24        FY25             - Further growth across consumables partially offset
                     Revenue                     GOR                     by reduced vaccine activity
                                                                    •   Medical Technology revenue grew by 18.6%
                                                                        (14.3% excl. acquisitions), driven by:
 $m                                FY25       FY24        Var%          - Strong growth across allografts, oncology,
     Revenue                       4,342      4,005          8.4%        orthopaedics, implants and capital sales in
      - Medicines, consumables     3,674      3,441          6.8%        Southeast Asia
        and other
      - Medical Technology          669          564      18.6%         - Double digit growth in Southeast Asia supported by

     GOR                            680          611      11.4%
                                                                         organic growth and supplemented with acquisitions
     GOR%                          15.7%      15.3%       40bps     •   GOR margin improved to 15.7%, reflecting
                                                                        expansion of the Medical Technology business



12
CONTRACT LOGISTICS
One of ANZ’s leading healthcare-focussed contract logistics providers



     GOR ($m)                                                                                                       • GOR was up 3.3% on the prior period, driven by:
                                                                                                                        -   New customer growth in Australia and New
                                                                                                                            Zealand, enabled by new warehouse capacity
                                                                                                                            installed over last two years
                                                      153                149                154
                                   129
                 92                                                                                                     -   Australian GOR increased by 15.4% due to major
                                                                                                                            new principal wins

            FY21                  FY22               FY23               FY24               FY25                         -   Full year impact of reduced demand of storage
                                                       GOR                                                                  and services for COVID-19 related products in
                                                                                                                            New Zealand

                                                                                                                    •    Continued investment in footprint and systems
     $m                                                  FY25                FY24                Var%                    planned:
            1
      GOR                                                  154                149                3.3%                   -   Opening a new Perth facility in 2026

                                                                                                                        -   Further cold storage expansion in Sydney
                                                                                                                            supporting GLP-1 and other speciality medicines




            1.        GOR is the primary financial performance metric for Contract Logistics. Sales are predominately on a consignment basis and therefore revenue and GOR margin (%) are less relevant metrics for this division. For reference,
13
                      revenue was $1,007m and $1,006m in FY25 and FY24, respectively.
     ANIMAL CARE SEGMENT
     ANZ’s largest dry dog food brand1 in pet specialty and ANZ’s leading vet wholesaler



     $m                                           FY25        FY24         Var%     • Revenue and EBITDA increased by 16.3% and 10.4% respectively, supported
     Revenue                                          673      579         16.3%      by the branded business and the acquisition of SVS. Excluding SVS, revenue and
                                                                                      EBITDA growth was 3.3% and 5.6% respectively
          Branded                                     335      322          4.1%
          Wholesale                                   339      257         31.6%    • Branded business delivered solid organic growth, driven by:
     GOR                                              215      195         10.1%     - Share gains of Black Hawk and VitaPet products
     Underlying EBITDA                                124      112         10.4%
                                                                                     - Partnerships and marketing activities
     GOR%                                        32.0%        33.7%       -170bps
                                                                                     - Growth from new product developments, supported by in-house
     Underlying EBITDA%                          18.4%        19.4%       -100bps
                                                                                       manufacturing capabilities
                                                                                    • Consumer environment continued to negatively impact discretionary categories
     Underlying EBITDA ($m and %)
                                                             19.4%
                                                                                    • Vet wholesale revenue grew 31.6% (2.3% excl. acquisition of SVS in April 2025).
                                                  17.7%                 18.4%
                                                                                      SVS business performed in-line with expectations
              13.9%             14.8%
                                                                                    • GOR margin was down -170bps due to the acquisition of a lower margin
                                                                                      business, SVS. Excluding SVS, GOR margin was 34.6%, up 90bps
                                                              112        124
                                                       99                           • FY26 will see continued expansion into new fast growing, higher margin pet
                 69                80
                                                                                      products, e.g. air-dried treats, through acquisition of Next Generation Pet Foods2

               FY21          FY22        FY23                FY24         FY25
                       Underlying EBITDA                    Underlying EBITDA%



     1.    Measured by volume
15
     2.    Acquisition was completed on 1 July 2025
     ACQUISITION OF NEXT GENERATION PET FOODS1
     Provides expansion into new high growth, high value products, and expands manufacturing capability




                                                                 • A Queensland based manufacturer and supplier of multi-format pet treats, with two
                                                                   facilities dedicated to manufacturing, packaging, order assembly and dispatch of premium
                                                                   products
                                                                 • Expands portfolio into new high growth, high value product categories, e.g. air-dried
                                                                   treats which are premium products and complementary to existing premium portfolio and
                                                                   supports international expansion plans
                                                                 • Enhances manufacturing capability and capacity
                                                                 • Additional distribution opportunity through emerging channels (e.g. club retailers and
                                                                   hardware)
                                                                 • Acquisition was fully funded through existing debt facilities and cash on hand, and is
                                                                   expected to be marginally EPS accretive in the first year




16   1.   Acquisition was completed on 1 July 2025
     GROUP PERFORMANCE
     The Group delivered strong revenue and Underlying EBITDA growth (excl. CWA)1 of 12.0% and 7.5% respectively



                                                                                                                Var%    • Revenue increased by 12.0% (excl. CWA)1, supported by both
          $m                                                 FY25              FY24               Var%        ex CWA1     Healthcare and Animal Care segments
           Underlying results2
           Revenue                                          12,267            13,189             (7.0%)        12.0%
                                                                                                                        • Underlying EBITDA increased by 7.5% (excl. CWA)1, with
                                                                                                                          margins up 10bps despite a competitive environment within
           GOR                                               1,637             1,633              0.3%         8.8%
                                                                                                                          Community Pharmacy
           Underlying EBITDA                                  585               624              (6.3%)        7.5%
           Depreciation & Amortisation                        120               103             (16.8%)       (16.8%)   • Depreciation & Amortisation increased by $17m, reflective of
           EBIT                                               465               522             (10.9%)        5.3%       ongoing capital investment to support future growth
           Net Finance Costs                                  106                94             (13.7%)
                                                                                                                        • Net Finance Costs increased by $12m due to lease interest costs
           Profit Before Tax                                  359               428             (16.2%)
                                                                                                                          associated with new sites and debt funding of investments
           Net Profit After Tax                               258               303             (15.1%)
           Earnings per share - cps                         131.3c             157.9c           (16.8%)                 • Underlying NPAT excludes one-off items of $42m (FY24: $32m),
           Underlying EBITDA%                                4.8%               4.7%             10bps                    associated with M&A transactions, non-recurring restructuring and
           Statutory results                                                                                              site transition costs, and PPA amortisation (non-cash)2
           Revenue                                          12,267            13,189             (7.0%)
           EBITDA                                             556               606              (8.3%)
           EBIT                                               409               477             (14.3%)
           Profit Before Tax                                  302               383             (21.1%)
           Net Profit After Tax                               215               272             (20.8%)
           Earnings per share - cps                         109.7c             141.3c           (22.4%)



     1.   Growth is FY25 Underlying compared to FY24 Underlying when normalised to exclude the CWA contract
18
     2.   Refer to page 29 for a reconciliation of Statutory to Underlying results
     CASH FLOW
     Strong cash generation
          Cashflow ($m)                                                             FY25               FY24               Var$
                                                                                                                                     • Cash flow before capex of $448m, supported organic growth
           Underlying EBITDA                                                         585                624                (39)        agenda, M&A strategy, shareholder returns and balance sheet
           Net interest                                                              (106)              (94)               (13)        management
           Tax                                                                       (82)              (104)                   21
                                                                                                                                     • Cash conversion days of 18 days, largely in line with the prior year
           Net working capital & other movements                                      52                (60)               112
                                                                                                                                     • Net working capital movement reflects unwind of CWA contract
           Underlying cash flow before capex                                         448                367                    81
                                                                                                                                       offset by investment to support business growth
           Capital expenditure                                                       (146)             (118)               (27)

           Underlying Free Cash Flow (FCF)1                                          302                249                    54

           One-off items                                                             (29)               (19)               (11)       Underlying Cash Flow Before Capex ($m)
           Reported Free Cash Flow                                                   273                230                    43

                                                                                                                                                                                                  44
          Working capital ($m) & cash conversion                                    FY25               FY24               Var$                                          4
                                                                                                                                                                                     3
           Net working capital2                                                                                                              3
           Trade & other receivables                                                1,514              1,495               (19)

           Inventory                                                                1,345              1,210              (135)

           Trade payables/other                                                    (2,472)            (2,270)              203

           Total                                                                     387                435                    49
                                                                                                                                             F            F            F             F            F
                               3
           Cash realisation                                                         109%                90%               19bps

           Cash conversion days                                                       18                 17                    (1)



     1.    Underlying Free Cash Flow excludes payments for one-off items
19   2.    Refer glossary for net working capital definition
     3.    Cash realisation calculated as (Underlying EBITDA plus net working capital & other movements) / Underlying EBITDA
     ORGANIC CAPITAL: DC RENEWAL PROGRAM CONCLUDES IN 2026
                                                                                             • DC renewal program has also achieved:
     Increased Healthcare distribution capacity over FY23-26
                                                                                              - Additional refrigeration footprint, that has
                                                                                                already enabled GLP-1 customer growth

            2023                 2024                 2025                   2026             - Operating efficiency gains, with automation
                                                                                                lowering cost to serve

                                                                                              - Enhanced system integration with customers
                                                                                                that streamline processes and improve service
                                                                                                delivery
      Contract Logistics:   Contract Logistics:     ProPharma:             Symbion:
           Sydney               Auckland             Auckland               Sydney           • Organic capital program to conclude in 2026
                                                                                               following commission of physical and IT
                            EBOS Healthcare:                              Onelink NZ:          infrastructure
                               Melbourne                                   Auckland
                                Sydney
                                                                       Contract Logistics:
                                                                             Perth

      Invested $360m (FY23-FY26) in Healthcare infrastructure and systems, delivering a
                  ~20% net increase of capacity and reduced cost to serve




20
     ACQUISITIONS
     Delivering value accretive M&A

     • Five1,4 investments executed for total consideration of $210 million, and are expected to generate $330 million of revenue on a full year basis
     • Acquisitions focused on building scale in core businesses and expanding presence across key channels and geographies
     • Bolt-on transaction size aligned to growth strategy and existing capital management framework
     • Acquisition pricing remains disciplined, with each investment expected to be EPS accretive immediately and strengthen ROCE over short to medium term
     • Acquisition pipeline remains active


                                                                                      1H FY25                                                      2H FY25                                      FY26 YTD
          Acquisition                                              Malex                         Pacific Surgical           Transmedic (100%)3                        SVS                 Next Generation Pet
                                                                                                                                                                                                Foods4
          Business                                        Medical Technology                    Medical Technology             Medical Technology                 Animal Care                    Animal Care

          Geography                                           Southeast Asia                       Southeast Asia                Southeast Asia                  New Zealand                      Australia

          Consideration2                                                     $31m for both companies                        $36m for remaining 10%                   $100m                          $43m
                                                                                                                                   interest
                                                        Specialist orthopaedic                  Specialist orthopaedic       A leading independent         A leading vet wholesaler in        Queensland based
          Description
                                                         device distributor in                 device distributor in the   medical device distributor in          New Zealand            manufacturer and supplier of
                                                               Malaysia                         Philippines focused on           Southeast Asia                                            multi-format pet treats
                                                         focused on implants                   implants relating to the                                                                   (refer page 16 for further
                                                     relating to sports medicine                  spine, sports, joints,                                                                         information)
                                                            and biologics                        biologics and capital
                                                                                                 equipment segments


     1.   Two additional small acquisitions were completed in FY25 and not noted above
     2.   Consideration includes upfront payment (excludes potential deferred consideration)
21
     3.   Increased shareholding in Transmedic from 90% to 100%
     4.   Includes Next Generation Pet Foods that was completed on 1 July 2025
     BALANCE SHEET
     Balance sheet and overall liquidity remains strong following debt refinancing and completion of capital raise



     Net debt and Leverage ratio1                                                                                    • Net debt of $918m, reduced by $101m, following successful
                                                                                                                       completion of a $254m capital raise in April 2025 to fund bolt-on
                     1.94x                                                        1.89x              1.92x
                                                   1.52x                                                               acquisitions

                                                                                                                     • Refinanced corporate debt facilities in H1 FY25, extending the
                                                                                                                       weighted average debt maturity to 2.9 years
                     860                                                          1,019              918
                                                    767
                                                                                                                     • Significant capacity and headroom in facilities & covenants, with
                                                                                                                       approximately ~$250m of debt headroom
                     FY22                          FY23                           FY24               FY25
                                                  Net debt                        Leverage ratio                     • Interest cost on borrowings in FY25 was $82m. FY26 net finance
                                                                                                                       costs are expected to be approximately $110 – 120m, assuming no
     Debt maturity profile ($m)
                                                                                                                       additional debt funding requirements
                                          700                                                  750
                                                                                                             552
                                          388
                                                                                               750
                                                                     193                                      551
                15                        312                         158

              FY26                       FY27                       FY28             FY29                    FY30+
                                                Drawn              Committed and available




22   1.   Calculated in accordance with banking covenants and excludes IFRS 16 lease impacts
     EARNINGS AND DIVIDENDS
     Aligning shareholder returns with earnings growth



     Underlying Earnings per Share (cents)                                                                                  • Underlying EPS of 131.3 cents, reflecting growth of Underlying business partially
                                                                                                                              offsetting loss of CWA contract
                                                 147.9              157.9
                              129.5                                                    131.3                                • Final dividend of NZ 61.5 cents per share, bringing total dividends for FY25 to
            114.9                                                                                                             118.5 cents per share, reflecting full year payout of 83.8%1 of Underlying NPAT.
                                                  73.3               78.4
                                63.0                                                    63.8                                  Dividend has been imputed to 25%2 and franked to 100% for New Zealand and
             57.2
                                                                                                                              Australian tax resident shareholders respectively
             57.8               66.6              74.5               79.5               67.5
                                                                                                                            • Dividend was maintained at the same level as FY24 and the increased payout
            FY21               FY22               FY23              FY24               FY25                                   ratio reflects the Board’s confidence in the Group’s growth outlook and overall
                                                                                                                              financial capacity
                                                 H1       H2
                                                                                                                            • The Group’s Dividend Reinvestment Plan (DRP) will be operational for the
     Dividends per Share (NZ cents)                                                                                           upcoming final dividend. Shareholders can elect to take shares in lieu of a cash
                                                                                                                              dividend at a discount of 2.5% to the volume weighted average share price (VWAP)
                                                 110.0              118.5              118.5
             88.5               96.0

                                                   57.0              61.5               61.5
             46.0               49.0

             42.5               47.0               53.0              57.0               57.0


            FY21               FY22               FY23               FY24              FY25

                                                 H1       H2

     1.   Dividend payout ratio is based on an Underlying basis on a NZD:AUD average exchange rate of 0.915.
23   2.   The New Zealand company tax rate is 28%. Therefore, a dividend that is partially imputed with 25% of the maximum allowable imputation credits implies an 8.86% imputation percentage in relation to the gross taxable amount of the
          dividend.
     FY26 OUTLOOK
                           •   Continued positive healthcare and animal care industry trends to support growth
     Market dynamics       •   Near-term macro pressures include: competitive wholesale pharmacy environment, soft hospital capital
                               spend, and subdued consumer sentiment impacting discretionary pet categories



                           •   Targeting Group Underlying EBITDA of $615 – 635m, reflecting ~7% midpoint growth,
     EBITDA growth         •   Positive growth contributions from both the Healthcare and Animal Care segments


                           •   In FY26, we expect capital expenditure of approximately $130 – 140m, marking the successful
     Capital expenditure       completion of our major distribution centre renewal program. In future years, annual capital expenditure
                               should be approximately 30% lower, on a comparable basis
     and D&A               •   Underlying depreciation and amortisation is expected to be approximately $140 – 150m, reflecting the
                               investments we’ve made in recent years and the increased capacity of our expanded distribution centres

                           •   Leverage remains within targeted range, with headroom to fund growth initiatives from existing liquidity
                               and balance sheet capacity
     Financing and tax     •   Net finance costs are expected to be approximately $110 – 120m, assuming no additional debt funding
                               requirements
                           •   The effective tax rate is expected to be approximately 28%



     Strategy              •   Investor day planned for Q4 FY26. Further details to come




                                                                 Ongoing advantage: trusted to connect to care


25
     INVESTMENT PROPOSITION
     A defensive growth care business underpinned by long-term industry trends, leading positions and strong capabilities


                                                                                       Increased pharma and                                                     Pet
                                                               Ageing population                                                         Pet ownership
                                                                                           medical spend                                                    humanisation
          Macro trends

                                                                       Increased healthcare spend                                              Increased pet spend


                                                                                                                Australia and New
                                                                       The leading health-services          Zealand’s leading hospital      ANZ’s largest dry dog food
                                 A leading pharmaceutical
                                                                          focussed community                medicines wholesaler and        brand1 in pet specialty and
          Leading positions      wholesaler in Australia and
                                                                         pharmacy network in                one of ANZ and Southeast            ANZ’s leading vet
                                       New Zealand
                                                                                Australia                     Asia’s leading medical                wholesaler
                                                                                                             technology distributors


                                                                                      Diversified trust driven businesses

                                                                                    Entrepreneurial results driven culture
          Shared EBOS
          capabilities
                                                                                           Supply chain excellence

                                                                                               M&A capability


          Outcome                                        Defensive growth care business with track record of strong financial performance



26   1.     Measured by volume
     SEGMENT INFORMATION
                                                                                        First Half                                           Second Half                                            Full Year

                                                                          Revenue                     GOR                       Revenue                     GOR                       Revenue                      GOR
                                                                                  1                         1                           1                         1                           1
     $m                                                           FY25     FY24       Var%     FY25   FY24      Var%    FY25     FY24       Var%     FY25   FY24      Var%    FY25     FY24       Var%     FY25    FY241   Var%
          Healthcare

          Community Pharmacy                                     3,144     2,802      12.2%    288    276       4.6%    3,312    2,771      19.5%    299    273       9.5%    6,456    5,574      15.8%    588      549    7.0%

          Institutional Healthcare                               2,157     1,966      9.7%     330    304       8.3%    2,185    2,039      7.2%     351    307       14.4%   4,342    4,005      8.4%     680      611    11.4%

              Medicines, consumables and other                    1,856    1,680      10.5%                             1,817    1,761       3.2%                             3,674    3,441       6.8%

              Medical Technology                                   301      285        5.5%                              368      278       32.1%                              669      564       18.6%

          Contract Logistics                                      492       524       (6.0%)    75     75       0.9%    514       482       6.8%     78      74       5.7%    1,007    1,006      0.1%     154      149    3.3%

          Sales eliminations                                      (107)    (106)      (0.8%)                            (105)    (104)      (0.9%)                            (212)    (210)      (0.8%)

          Total                                                  5,687     5,186      9.7%     694    655       5.9%    5,906    5,188      13.9%    728    654       11.4%   11,593 10,374 11.8%          1,422   1,309   8.6%


          Animal Care

          Branded                                                 167       156       7.6%                              167       166       0.8%                               335      322       4.1%

          Wholesale                                               137       130       4.8%                              202       127       59.1%                              339      257       31.6%

          Total                                                   304       286       6.3%     106     94       12.2%   369       293       26.1%    109    101       8.2%     673      579       16.3%    215      195    10.1%


          EBOS Group

          Total                                                  5,991     5,473      9.5%     799    749       6.7%    6,275    5,480      14.5%    838    755       10.9%   12,267 10,953 12.0%          1,637   1,504   8.8%




28   1.    FY24 Revenue and GOR normalised to exclude the CWA contract
     RECONCILIATION OF STATUTORY TO UNDERLYING RESULTS
                                                                         FY25                                                        FY24

     $m                                         Revenue     EBITDA       EBIT        PBT        NPAT        Revenue     EBITDA       EBIT        PBT          NPAT
      Statutory result                           12,267       556         409        302         215         13,189       606        477         383          272

      M&A transaction costs                         -          11         11          11         10             -         10          10         10            7

      Restructuring & site transition costs         -          18         18          18         13             -          9          9           9            6

      PPA amortisation (non-cash)                   -          -          27          27         19             -          -          26         26            18

      Total underlying earnings adjustments         -          29         56          56         42             -         19          45         45            32

      Underlying result                          12,267       585         465        359         258         13,189       624        522         428          303

      CWA estimated earnings                        -          -           -                                 (2,236)      (80)       (80)

      Underlying result excluding CWA            12,267       585         465                                10,953       544        442




     • FY25 and FY24 Underlying earnings exclude one-off M&A transaction costs, non-recurring restructuring and site transition costs and the amortisation (non-
       cash) expense attributable to acquisition PPA of finite life intangible assets
     • To provide a like-for-like comparison to the prior corresponding period, where applicable, this presentation includes comparisons against underlying
       earnings exclusive of the estimated earnings from the Chemist Warehouse Australia (CWA) contract for the 30 June 2024 period




29
     SEGMENT EBITDA AND EBIT RECONCILIATION
                                                         EBITDA                    EBIT
     $m                                           FY25    FY24    Var %     FY25   FY24    Var%
      Healthcare
      Statutory                                   472     537     (12.2%)   339    420    (19.3%)
      Add M&A transaction costs                    10       2                10      2
      Add Restructuring & site transition costs    18       9                18      9
      Add PPA amortisation (non-cash)               -       -                27     26
      Total underlying earnings adjustments        28      11                55     37
      Underlying result                           500     548     (8.7%)    394    457    (13.8%)
      CWA estimated earnings                        -     (80)                -    (80)
      Underlying result excluding CWA             500     468      6.9%     394    377     4.5%

      Animal Care
      Statutory                                   123     104     17.8%     110     93    17.5%
      Add M&A transaction costs                    1       8                 1       8
      Underlying result                           124     112     10.4%     111    101     9.3%

      Corporate
      Statutory                                   (39)    (36)    (9.0%)    (40)   (37)   (8.4%)

      EBOS Group
      Statutory                                   556     606     (8.3%)    409    477    (14.3%)
      Add M&A transaction costs                    11      10                11     10
      Add Restructuring & site transition costs    18       9                18      9
      Add PPA amortisation (non-cash)               -       -                27     26
      Total underlying earnings adjustments        29      19                56     45
      Underlying result                           585     624     (6.3%)    465    522    (10.9%)
      CWA estimated earnings                        -     (80)                -    (80)
      Underlying excluding CWA                    585     544      7.5%     465    442     5.3%




30
     GLOSSARY OF TERMS AND MEASURES
     Except where noted, common terms and measures used in this document are based upon the following definitions:
      Term                                 Definition
      Revenue                              Revenue from the sale of goods and the rendering of services
      Gross Operating Revenue (GOR)        Revenue less cost of sales and the write-down of inventory
      Underlying Operating Expenditure     Operating expenditure excluding depreciation and amortisation excluding one-off items
      EBITDA                               Earnings before interest, tax, depreciation and amortisation
      Underlying EBITDA                    Earnings before interest, tax, depreciation, amortisation adjusted for one-off items
      EBIT                                 Earnings before interest and tax
      Underlying EBIT                      Earnings before interest and tax and adjusted for one-off items and LifeHealthcare PPA amortisation (non-cash)
      PBT                                  Profit before tax
      Underlying PBT                       Profit before tax adjusted for one-off items and LifeHealthcare PPA amortisation (non-cash)
      NPAT                                 Net Profit After Tax attributable to the owners of the company

      Underlying NPAT                      Net Profit After Tax attributable to the owners of the company adjusted for one-off items and LifeHealthcare PPA amortisation (non-cash and after tax)
      One-off items                        Non-recurring impacts including M&A transaction costs, restructuring and site transition costs, integration costs and tax legislation changes
      Earnings per share (EPS)             Net Profit after tax divided by the weighted average number of shares on issue during the period in accordance with IAS      ‘Earnings per share’
      Underlying EPS                       Underlying NPAT divided by the weighted average number of shares on issue during the period
      Free Cash Flow                       Cash from operating activities less capital expenditure net of proceeds from disposals

      Underlying Cash from Operations      Cash from operating activities excluding payments for one-off items

      Underlying Free Cash Flow            Free cash flow excluding payments for one-off items
      Net Working Capital                  Trade and Other Receivables, Inventory, Prepayments, Trade and Other Payables (excluding deferred purchase consideration) and Employee Benefits.
      Net Debt                             Bank loans less cash and cash equivalents
                                           Ratio of net debt at period end to the last 12 months Underlying EBITDA, adjusting for pre acquisition earnings of acquisitions for the period. Calculation is applied as per the Group’s
      Leverage Ratio / Net Debt : EBITDA
                                           banking covenants and excludes IFRS16 lease impacts.
      Cash realisation                     (Underlying EBITDA less net working capital & other movements) / Underlying EBITDA
      Cash Conversion Days                 Based upon average monthly closing NWC balances for the financial period
                                           Underlying earnings before interest, tax and amortisation of finite life intangibles for 12 months divided by closing capital employed (excluding IFRS16 Leases and with a pro-rata
      Return on Capital Employed (ROCE)
                                           adjustment for strategic investments)
      CAGR                                 Compound Annual Growth Rate
      IFRS                                 International Financial Reporting Standards
      PPA                                  Purchase Price Accounting



31
www.ebosgroup.com
